Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring.

ABSTRACT:

Background

Serum biomarkers can improve diagnosis and treatment of malignant pleural mesothelioma (MPM). However, the evaluation of potential new serum biomarker candidates is hampered by a lack of assay technologies for their clinical evaluation. Here we followed a hypothesis-driven targeted proteomics strategy for the identification and clinical evaluation of MPM candidate biomarkers in serum of patient cohorts.

Results

Based on the hypothesis that cell surface exposed glycoproteins are prone to be released from tumor-cells to the circulatory system, we screened the surfaceome of model cell lines for potential MPM candidate biomarkers. Selected Reaction Monitoring (SRM) assay technology allowed for the direct evaluation of the newly identified candidates in serum. Our eval

SUBMITTER: Cerciello F 

PROVIDER: S-EPMC3827840 | biostudies-literature | 2013 Nov

REPOSITORIES: biostudies-literature